Scholarlink

<p>The role of axillary lymph node dissection (ALND) in breast cancer patients with sentinel lymph node (SLN) micrometastases, particularly after neoadjuvant therapy, remains debated. The present study aimed to assess whether adding ALND provides a survival benefit in this population. Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database (2010–2021) and a validation cohort from the First Affiliated Hospital of Xi’an Jiaotong University (2018–2024) for female breast cancer patients with SLN micrometastases (pTxN1miM0) after neoadjuvant therapy. Machine learning techniques (LASSO, random forest, and SVM-RFE) were used to identify key prognostic factors. Survival analyses were conducted using Kaplan‒Meier, Cox regression, and competing risk models to evaluate the impact of ALND on overall survival (OS), disease-free survival (DFS), breast cancer-specific survival (BCSS), and death from other causes (OCSD). After propensity-score matching, 2166 patients from the SEER cohort and 116 from the hospital cohort were included. Survival analysis revealed no significant differences in OS (HR 1.26, <i>P</i> = 0.118), BCSS (HR 1.16, <i>P</i> = 0.378), or DFS (HR 1.88,<i> P</i> = 0.239) between the sentinel lymph node biopsy (SLNB) only group and the SLNB with complete ALND group. No significant differences in the BCSD (<i>P</i> = 0.378) or OCSD (<i>P</i> = 0.121) were found. Machine learning identified 10 prognostic factors, and higher tumor grade, T stages 3–4, PR-negative status, and HER2-negative status were identified as independent unfavorable factors. ALND does not improve survival in breast cancer patients with SLN micrometastases after neoadjuvant therapy. These findings support a more conservative approach to axillary management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Axillary lymph node dissection offers no survival benefit in breast cancer patients with sentinel lymph node micrometastases after neoadjuvant therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月25日

查看全文
  • Jianing Zhang,
  • Yudong Zhou,
  • Lizhe Zhu,
  • Jiaqi Zhang,
  • Chenglong Duan,
  • Jinsui Du,
  • Yi Pan,
  • Yalong Wang,
  • Danni Li,
  • Yu Ren,
  • Bin Wang

摘要

The role of axillary lymph node dissection (ALND) in breast cancer patients with sentinel lymph node (SLN) micrometastases, particularly after neoadjuvant therapy, remains debated. The present study aimed to assess whether adding ALND provides a survival benefit in this population. Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database (2010–2021) and a validation cohort from the First Affiliated Hospital of Xi’an Jiaotong University (2018–2024) for female breast cancer patients with SLN micrometastases (pTxN1miM0) after neoadjuvant therapy. Machine learning techniques (LASSO, random forest, and SVM-RFE) were used to identify key prognostic factors. Survival analyses were conducted using Kaplan‒Meier, Cox regression, and competing risk models to evaluate the impact of ALND on overall survival (OS), disease-free survival (DFS), breast cancer-specific survival (BCSS), and death from other causes (OCSD). After propensity-score matching, 2166 patients from the SEER cohort and 116 from the hospital cohort were included. Survival analysis revealed no significant differences in OS (HR 1.26, P = 0.118), BCSS (HR 1.16, P = 0.378), or DFS (HR 1.88, P = 0.239) between the sentinel lymph node biopsy (SLNB) only group and the SLNB with complete ALND group. No significant differences in the BCSD (P = 0.378) or OCSD (P = 0.121) were found. Machine learning identified 10 prognostic factors, and higher tumor grade, T stages 3–4, PR-negative status, and HER2-negative status were identified as independent unfavorable factors. ALND does not improve survival in breast cancer patients with SLN micrometastases after neoadjuvant therapy. These findings support a more conservative approach to axillary management.